TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Alcohol-related Problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pleural fluid attenuation value measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcerative Colitis remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crohn Disease remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-8 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-6 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emotional dysregulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients With at Least 1 Treatment-emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in proportion of patients with normal vitamin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in DBP and SBP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NCI.CTC Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Psychiatric symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum Cell Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sputum Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time of bringing down the fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of body temperature going back to normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cure of Stress Urinary Incontinence (SUI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Signs and Symptoms Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with BVAS=0 and prednisone dose ≤7.5 mg/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall remission rate (ORR)
Endpoint domain: Physiological/clinical
Primary endpoint: levels of nano particles and arsenic in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to screening guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Half-life of intracellular raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time course of intracellular raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall rate of antibiotic prescribing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of Oxygen Saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs) Grades 3-5
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Multiple C16G2 Varnish Applications
Endpoint domain: Adverse events/effects
Primary endpoint: PAED Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic muscle injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NCC cotransporter expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Readiness to disclose HIV serostatus
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disclosure of HIV serostatus
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Talar cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tibialis anterior muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gastrocnemius muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Alcoholic drinks per occasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional status of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of biopsy of tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fat measured by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyetracking performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot deformity in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Who Are Progression Free at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Continuous variable outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Categorical variable outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multivariable outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) in patients with severe thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration (Cmax) in patients with severe thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) in patients without severe thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration (Cmax) in patients without severe thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Experienced at Least 1 AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced at Least 1 Causally Related AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least 1 AE of CTCAE >=G3
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence rate of adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of occurrences of unprotected sex
Endpoint domain: Adverse events/effects
Primary endpoint: Stage of change for condom use
Endpoint domain: Life impact
Endpoint subdomain: Behavioral change
Primary endpoint: Detection rate agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Prostate Specific Antigen (PSA) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric quadriceps-force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Subjects Who Are Benzodiazepine Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital mortality truncated at 60 days
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Oedema
Endpoint domain: Adverse events/effects
Primary endpoint: safety and tolerability of POL6326
Endpoint domain: Adverse events/effects
Primary endpoint: number of allogeneic donors requiring a second leukapheresis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in thermal quantitative sensory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pressure quantitative sensory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of readings below 54 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Objective Response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose of IT-141
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrovascular Accident (CVA)
Endpoint domain: Mortality/survival
Primary endpoint: Transient Ischemic Attack (TIA)
Endpoint domain: Mortality/survival
Primary endpoint: Change of gross motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Confirmed Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative measures at 15th minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative measures at 30th minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative measures at 60th minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Progression at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Y-MRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality (ICU)
Endpoint domain: Mortality/survival
Primary endpoint: Mortality (60-day)
Endpoint domain: Mortality/survival
Primary endpoint: Global Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients successfully administered Nelfinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete re-epithelization of the lesion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number and severity of all adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Coenzyme Q10 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in QTcI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in voice acoustics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flicker induced vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of budesonide-formoterol combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of budesonide-formoterol combination
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in regional brain hemodynamic response during attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in NYHA classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression of thoracic aortic calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Corrected QT prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone density measured by Visual Analog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence and volume of hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Objective Memory Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: % adherence to each pharmacological class
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of occurrence of medical events at 1 year
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle Osteoarthritis Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tumor Marker CA125
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Marker HE4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Differences in composition of the fecal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Weight Bearing Absolute difference between lower limbs (ΔWBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-efficacy to meet Guidelines
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of the affected hand and arm in bimanual performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality of the affected hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS heat score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Area of Thyroid Nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Curve From Predose to 48 Hours Post-dose (AUC48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Predose to Extrapolated Infinite Time (AUC Infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Atrial Arrhythmias or Prescription of Anti-arrhythmic Drug or Re-ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary Safety Event (Composite of Death, Stroke, and Serious Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Association of RAPID results with oral cavity / oropharyngeal biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Association of RAPID results with the clinical decision process for avoiding an immediate biopsy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma Area under the curve (AUC) of chlorogenic and phenolic acid metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in EASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean change in HADS anxiety sub-score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient's perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Subjects With Total Daily Insulin Dose < 0.5 U/kg/Day and HbA1c < 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in sagittal spinal alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Fractalkine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Global Health Status/Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to removal of nasogastric tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of undernutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's satisfaction with surgical gloves
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of peripheral neuropathies
Endpoint domain: Adverse events/effects
Primary endpoint: Change in posttraumatic stress disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-contrast head CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Objective Response Rate (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PGC-1α mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the OSOM Rapid Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity of PCR Wet Mount Microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of days abstinent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in dose estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episiotomy procedures
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: COPD Assessment Tool (CAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in a marker of collagen synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in a marker of collagen breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dominant power hand grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in testicular vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: American Shoulder And Elbow Surgeons Shoulder Index (ASES)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of intracranial arterial wall abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in mean daily number of steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor traumatic brain injury symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline scores on the Clinician Administered PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline scores on the PTSD Symptom Checklist (PCL, self-reported)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydroxyurea adherence ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of cardiac autonomic neuropathy (CAN) and diabetic autonomic neuropathy (DAN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of allergen-induced eosinophils in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anxiety-state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete Clinical Response (cCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score (AUC based on NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a Community Peridontal Index (CPI) ≥3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Resolution of Gastrointestinal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hyaluronic acid concentration in facial skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intra ocular measurements differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: AEs leading to discontinuation or death
Endpoint domain: Adverse events/effects
Primary endpoint: DNA oxidative damage levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of reported cases of AOM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Induction response prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in cytokine genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in 28-joint disease activity index (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in European league against rheumatism (EULAR) response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery/Improvement in Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dose of Propofol Required to Prevent Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Fatigue Impact Scale (FIS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in Patient-Reported Outcomes Measurement Information System (PROMIS) - Short Form Ver 1.0 Fatigue 8a
Endpoint domain: Life impact
Endpoint subdomain: Fatigue